DocGo’s (DCGO) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of DocGo (NASDAQ:DCGO) in a report published on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $3.00 target price on the stock.

DCGO has been the subject of several other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 price objective on shares of DocGo in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of DocGo in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $2.50.

DocGo Trading Up 20.1%

DCGO opened at $0.78 on Tuesday. The stock has a 50-day moving average of $0.77 and a 200 day moving average of $1.02. DocGo has a 12 month low of $0.60 and a 12 month high of $2.88. The firm has a market cap of $76.05 million, a P/E ratio of -0.42 and a beta of 0.95.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DCGO. Bridgeway Capital Management LLC boosted its stake in DocGo by 3.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 370,699 shares of the company’s stock worth $504,000 after purchasing an additional 12,942 shares during the last quarter. Jane Street Group LLC raised its position in shares of DocGo by 18.8% in the first quarter. Jane Street Group LLC now owns 85,442 shares of the company’s stock valued at $226,000 after buying an additional 13,505 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of DocGo by 3.0% in the fourth quarter. Franklin Resources Inc. now owns 563,983 shares of the company’s stock worth $495,000 after buying an additional 16,637 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of DocGo by 14.6% in the fourth quarter. Empowered Funds LLC now owns 138,306 shares of the company’s stock worth $121,000 after buying an additional 17,607 shares in the last quarter. Finally, Cerity Partners LLC acquired a new position in DocGo during the second quarter worth about $37,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Trending Headlines about DocGo

Here are the key news stories impacting DocGo this week:

• Positive Sentiment: Q4 revenue beat and market reaction — DocGo reported Q4 revenue of $74.9M, above consensus, and shares reportedly jumped (~15%) on the topline beat and upbeat commentary. Investing.com: DocGo shares surge
• Positive Sentiment: 2026 guidance and strategic review — management set 2026 revenue guidance of $290M–$310M, reiterated a path to profitability and said it is exploring strategic alternatives, which could unlock value or lead to a sale/transaction. Seeking Alpha: 2026 guidance & strategic alternatives
• Positive Sentiment: Analyst support — Cantor Fitzgerald reaffirmed an “overweight” rating with a $3 PT and Needham & Company reaffirmed a “buy” with a $3 PT, signaling continued institutional bullishness despite volatility. Benzinga: Cantor/Needham coverage
• Neutral Sentiment: Stifel revises target down — Stifel cut its price target from $4.00 to $2.50 but kept a “buy” rating, reducing near-term upside expectations while remaining constructive. Benzinga: Stifel lowers target
• Neutral Sentiment: Earnings call / transcripts available — management discussed the quarter, guidance and strategic alternatives on the Q4 2025 call; read the transcript for color on margin timing and capital allocation. MSN: Q4 2025 earnings call transcript
• Negative Sentiment: Large EPS miss and profitability pressure — DocGo reported a substantial GAAP loss for the quarter (wide of consensus) and negative margins/ROE, which underscore near-term profitability risks despite revenue growth in some areas. MarketBeat: Q4 results overview
• Negative Sentiment: YoY revenue drop in core operations — the company noted Q4 revenue declined versus prior year primarily due to the wind-down of a legacy business line, contributing to mixed investor reaction and continued execution risk. BusinessWire: Q4 & FY2025 results

About DocGo

DocGo, Inc is a U.S.-based integrated healthcare company that delivers on-demand and mobile healthcare services. The company’s business model centers on deploying customized medical clinics paired with a digital care platform to bring primary and acute care directly to patients. Through a combination of telemedicine and over-the-road medical units, DocGo addresses routine medical exams, chronic disease management, occupational health screenings, specialist consultations and urgent care interventions.

In addition to its mobile clinic fleet, DocGo’s digital platform offers 24/7 virtual care, facilitating remote consultations via video, phone or secure messaging.